Cipla Limited reported a 39.2% year-on-year decline in consolidated net profit to ₹785.55 crore for the quarter ended June 30, 2026, down from ₹1,291.61 crore in the corresponding period of the previous year. The decline was driven by margin contraction and exceptional costs related to new labour codes, even as revenue registered modest growth. The Board of Directors approved the unaudited financial results at its meeting held on July 23, 2026.

Q1 Financial Performance

Total revenue from operations for the quarter stood at ₹7,119.28 crore, a 2.3% increase compared to ₹6,957.47 crore in Q1FY26. However, total expenses rose to ₹6,248.25 crore from ₹5,446.10 crore year-on-year. The company reported an exceptional loss of ₹275.91 crore in the previous fiscal year ended March 31, 2026, primarily due to an incremental gratuity and leave liability arising from the implementation of the New Labour Codes effective November 21, 2025.

Operational and Regulatory Updates

The company noted that effective April 1, 2026, it changed its presentation policy for marketing and promotional expenditures, now recording them as a reduction from Revenue from Operations rather than under Other Expenses. This change impacts revenue comparability but does not affect Profit for the period or Earnings per Share. Additionally, the paid-up equity share capital increased to ₹161.57 crore during the quarter following the allotment of shares under employee stock option schemes.

Cipla continues to face demand notices from the National Pharmaceutical Pricing Authority (NPPA) regarding alleged overcharges. The aggregate amount under litigation stands at ₹2,011 crore, comprising a principal of ₹863 crore and interest of ₹1,148 crore. The company has stated it expects a favourable outcome and has not made any provisions for these demands.

Segment Performance

One India delivered its highest-ever quarterly revenue of ₹3,452 crore, growing 12% year-on-year. This performance was driven by double-digit growth in chronic therapies such as Respiratory, Urology, Anti-diabetes, and Cardiac. The company maintained its rank as the second-largest player in overall chronic therapies, with the chronic mix improving to 60.4%. Key brands like Foracort, Duolin Syncrobreathe, and Doloneuron contributed to the growth.

North America reported revenue of $162 million, highlighted by the launch of the first AB-rated gVentolin with Complex Generic Technology (CGT). One Africa revenue stood at $103 million, up 1% year-on-year, with South Africa's private business growing faster than the market. Emerging Markets and Europe recorded revenue of $106 million, a 5% increase, continuing their growth trajectory.

Cipla has received continued endorsement from three prominent global brokerages — Nomura, Citi, and JPMorgan — all of whom have maintained their bullish ratings on the pharmaceutical major following its latest quarterly results. Despite Q1 EBITDA margins coming in below estimates, the company's retention of its FY27 margin guidance has been a key reassurance for analysts across the board.

Brokerage Ratings and Target Prices

The following table summarises the ratings and target prices assigned by each brokerage:

Nomura: Margin Recovery Hinges on High-Value US Launches

Nomura has maintained its Buy rating on Cipla with a target price of ₹1,510. The brokerage acknowledged that Q1 EBITDA margins missed estimates but highlighted that the company retained its FY27 margin guidance. Nomura views high-value US product launches as a key driver expected to support margin recovery going forward.

Citi: India Growth and US Launches Support Earnings Upside

Citi has also retained its Buy rating with a target price of ₹1,700, the highest among the three brokerages. According to Citi, Q1 performance was largely in line with expectations. The firm pointed to robust India business growth and improving US product launches as factors supporting potential earnings upside in FY28, alongside the company's retained FY27 margin guidance.

JPMorgan: Strong US Pipeline and Operating Leverage in Focus

JPMorgan maintained its Overweight rating on Cipla with a target price of ₹1,600. Similar to its peers, JPMorgan noted that Q1 EBITDA margins fell short of estimates. However, the brokerage cited the company's retained FY27 margin guidance, a strong US launch pipeline, and operating leverage as the primary factors underpinning its positive stance.

Key Themes Across Brokerages

Several common themes emerge from the three brokerage assessments:

• Q1 EBITDA margin miss: All three brokerages acknowledged that Q1 margins came in below estimates.
• FY27 margin guidance retained: Cipla's decision to maintain its FY27 margin guidance was a consistent positive highlight across all three reports.
• US launch pipeline: High-value and improving US product launches were cited as a critical growth and margin recovery lever.
• India business strength: Citi specifically noted robust India growth as a supporting factor for future earnings.
• Operating leverage: JPMorgan flagged operating leverage as an additional tailwind for margin improvement.